Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

PENN Entertainment Inc PENN

PENN Entertainment, Inc. is a provider of integrated entertainment, sports content and casino gaming experiences. The Company operates over 43 properties in 20 states, online sports betting in 18 jurisdictions and iCasino in five jurisdictions, under a portfolio of brands, including Hollywood Casino, L’Auberge, ESPN BET, and theScore Bet Sportsbook and Casino. Its segments include Northeast, South, West, Midwest, and Interactive. The Northeast segment include Ameristar East Chicago, Hollywood Casino Columbus, Hollywood Casino at Greektown, and Hollywood Casino at PENN National Race Course. The South segment includes 1st Jackpot Casino, Ameristar Vicksburg, Boomtown New Orleans, and L’Auberge Baton Rouge. The West segment include Ameristar Black Hawk, M Resort, and Zia Park Casino. The Midwest segment includes Ameristar Council Bluffs, Hollywood Casino Aurora, and River City Casino. Its Interactive segment includes online sports betting, iCasino and online social gaming operations.


NDAQ:PENN - Post by User

Post by EfraineJaron Apr 19, 2022 1:03am
315 Views
Post# 34612236

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS Video


FSD Pharma is delighted to announce pre-clinical findings indicating the efficacy of Lucid-MS, its flagship medication candidate, in treating Multiple Sclerosis. Lucid-MS's therapeutic potential is an industry first, and we'd like to provide visual evidence of functional recovery in pre-clinical individuals in this video!

<< Previous
Bullboard Posts
Next >>